OREANDA-NEWS. MDxHealth SA announced today, pursuant to Article 15 of the Belgian Act of May 2, 2007 on the publication of significant shareholdings in issuers which shares are admitted to trading on a regulated market, that on May 19, 2016, 116,000 new ordinary shares were issued by MDxHealth further to the exercise of 116,000 warrants by employees and consultants of MDxHealth, for an aggregate exercise price of € 196,920.00 for all warrants. The exercised warrants were initially issued in April 2011 and May 2012.

As a result of the aforementioned exercise of warrants, the share capital of MDxHealth increased from € 36,018,550.66 to € 36,111,083.86 and the number of outstanding shares increased from 45,153,633 to 45,269,633 shares.

On the date of this press release, the total number of existing warrants (whether or not already granted or already vested) amounts to 2,087,063 warrants which (if exercised) would entitle their holders to 2,087,063 shares with voting rights. All outstanding shares have voting rights.

MDxHealth is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. The company's tests are based on proprietary gene methylation (epigenetic) and other molecular technologies and assist physicians with the diagnosis of cancer, prognosis of recurrence risk, and prediction of response to a specific therapy.